Psychosomatic Interrelations in Cardiovascular Diseases and Their Consequences on Patient’s Quality of Life by Suciu, Maria & Cristescu, Carmen
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Psychosomatic Interrelations in Cardiovascular
Diseases and Their Consequences on Patient’s Quality
of Life
Maria Suciu and Carmen Cristescu
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.69699
Abstract
At present, the cardiovascular diseases (CVD) are among the major concerns of World 
Health Organization (WHO), assurance health systems and researchers in the specific 
field, because they are the number one cause of deaths globally, and according to several 
perspective studies, they will become the pathology that generates the greatest economic 
burden worldwide, through morbidity, disability, poor quality of life, and cause of death. 
Nowadays, the psychic field and the vulnerability of individual mental level to stress 
are an important link in the development of mental illness, CVD (included in the group 
of psychosomatic disorders), and also of interrelationship between them. The combined 
effects of these factors are reflected in the behavioral and cardiovascular (CV) system’s 
pathophysiological changes, which determine the impairment of health-related quality 
of life for the CV patients, on both short-term and long-term. This chapter aims to address 
both the interrelationship of psychosocial factors with CVD in terms of its multifactorial 
etiology and the mark of this bidirectional link on the quality of life of the patients. In 
several sections, the following issues will be described: general aspects regarding the 
relationship between homeostasis-stress-pathology; the role of stress as a psychosocial 
factor in the multifactorial etiology of CVD; the implications of mental disorders in the 
pathogenesis of CVD; behavioral aspects of CV patient during his illness, and strategies 
for improving therapeutic adherence and the quality of life of these patients.
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1. Introduction
In 1978, World Health Organization (WHO) defines health not only as a mere absence of 
disease or infirmity but as a state of complete well-being, physically, mentally, and socially. 
Also, in 2013, in its report regarding the global health, the same organization specifies that the 
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cardiovascular diseases (CVD) are the leading cause of premature adult death in the world, 
and one of the major causes of disability worldwide. In Europe, statistics of the European 
Commission (EUROSTAT) on causes of death identified CVD as occupying the first position 
in the 2013 ranking [1]. All these determine a cost increase in the health insurance system 
and a decrease in the individuals’ quality of life (QOL). According to the 2016 recommenda-
tions of the European Society of Cardiology [2], prevention of CVD is a major public health 
objective. Due to an increased prevalence of CVD in the general population and a negative 
effect on both social and economic status today, they are considered “civilization diseases” 
[3]. Numerous clinical studies have revealed a very close correlation between the occurrence 
of cardiovascular (CV) pathology, genetic, and life style factors and modifiable physiological 
and biochemical factors during the individuals’ lifetime. Also, it was demonstrated that a 
better management of the traditional modifiable CV risk factors (through measures of thera-
peutic education of the patient) may help reduce mortality and morbidity from CVD in the 
general population, especially in patients who have an increased risk of developing complica-
tions [4]. In recent decades, researchers’ attention was directed toward other CV risk factors, 
including nontraditional psychosocial variables. These risk factors, insufficiently approached 
before, but potentially modifiable, have become object of the INTERHEART study, including 
one called “psychosocial stress” (and reunited under the name of psychosocial factors) [5]. 
An association between emotions and CVD was observed since ancient times. Hence, clini-
cal observations of Hippocrates and Galien led to the establishment of the four fundamental 
human temperaments: sanguine, choleric, melancholic, and phlegmatic. The effect of negative 
emotions (e.g., anger, anxiety, and depression) on the health of the individual is already a well 
known, fact sustained by several clinical trials. Nowadays, the anxiety and mood disorders 
are widely recognized as two psychosocial factors, the presence of which has been observed 
in a large number of patients with CVD.
2. General aspects regarding the relationship between 
homeostasis—stress—pathology
2.1. The concepts of homeostasis and stress
The “homeostasis” term was first introduced in medicine by Hippocrates and its dysregula-
tion consequences were called pathologies. “Any dyscrasia or rupture of the normal equilib-
rium is the cause of diseases” [6]. Walter Bradford Cannon, a Harvard physiologist, connects 
the concept of homeostasis and the concept of stress in 1915, and 20 years later, in 1935 he rec-
ognizes that the connectedness is a secretion of adrenaline produced by the adrenal medulla, 
consequence of an adaptive hyperfunction of the sympathetic nervous system (SNS), required 
to maintain normal limits of homeostasis [7]. The structures by which the body controls and 
regulates its own homeostasis are the interventions of the central nervous system (CNS), auto-
nomic, endocrinal, and immune systems. The main control mechanism at the base homeostasis 
is a negative “feedback.” The concept of “mental stress” was first introduced in 1956 and per-
fected over many decades of research by Hans Selye, pioneering endocrinologist, recognized 
as the “father of stress,” who defined it as “the nonspecific response of the body to a series of 
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external stressor agents of physical, chemical, biological, and psychological origin” and which 
can trigger future pleasant or unpleasant events. He depicted the existence of two stress-
response syndromes, one local and one general [8]. Local adaptation syndrome is a localized 
response, limited to the aggression area of the stress agent, immediate and short-termed, and 
manifested by an acute inflammatory response, while the general adaptation syndrome is 
defined by a general reaction of the body, it is a long-term reaction and involves the activation 
of the CNS by neuroendocrine axis, hypothalamic-pituitary-adrenal axis (HPA axis), and the 
autonomic nervous system (ANS) through the SNS [8]. Nevertheless, this biological theory of 
Hans Selye is just a description of adaptive physiological reactions to the presence of stress 
factors and discusses only the behavior of different organ systems and omits one’s subjective 
perception of stressful situation emerging in one’s life, the relational, cognitive, behavioral, 
and affective aspects that can develop after such a situation being ignored. In the context of 
the new approach, in 1984, R. Lazarus defines stress in a broader sense and comes up together 
with Folkman with the model “Theory of Cognitive Appraisal,” which explained the mental 
process that influences the stressors [9].
2.2. Biological stress effects on the body
The systemic response to stress is a general nonspecific reaction and has at its base the inter-
vention of numerous biological systems, two of which are major components: local and CNS 
through neuroendocrine axis and immune axis, but particular roles in modulating it play the 
basal nuclei, hippocampus, and amygdala [10].
2.2.1. The role of the amygdala and hippocampus in the stress response
The subjective perception of the stimuli is possible due to the intervention of two limbic 
structures: the amygdala and the hippocampus. The amygdala is a meeting point for neuro-
nal sensory afferents for most perceptions that receive information from the entire cortex it 
generates efferent to the hypothalamus and thus modulates the ANS and the hypothalamo-
hypophyseal axis [8]. The amygdala affects the emotional valence of sensory stimuli playing a 
very important role in the behavioral response and facial expressions associated with feelings 
of fear and anxiety. Both of them being involved, the thalamus and the amygdala activate 
an almost immediate response for fear [11, 12]. The hippocampus is, on the other hand, a 
structure designed to generate an appropriate behavioral response to a stimulus. Through 
functional integration of the two structures, it is possible to adapt the individual’s vigilance 
and attention to stress [11, 12].
2.2.2. Neuroendocrine axis response to stress
This type of response is triggered and modulated by the hypothalamus that integrates received 
afferents and is highly interconnected with other parts of the CNS, limbic system, and ascending 
reticular activating system (ascending RAS) and is also connected with areas of the ANS through 
the locus coeruleus-norepinephrine system which is the principal site for brain synthesis of nor-
adrenaline, and the HPA axis by the release of the corticotropin-releasing hormone (CRH) [13]. 
The role of the cerebral cortex is to increase alertness and attention through incoming afferents 
Psychosomatic Interrelations in Cardiovascular Diseases and Their Consequences on Patient’s...
http://dx.doi.org/10.5772/intechopen.69699
81
by thalamus and ascending RAS, under stress conditions; the role of the limbic system is to 
imprint the emotional component to the stress response (manifested by states of fear, anger, joy, 
or elation), while the ascending RAS is the one that induces the cortical alertness state (mani-
fested by vigilance and excitement), increasing the activity of SNS and reactive of the muscle 
tone [13]. In the periphery, the neuroendocrine axis response to stress is mediated through the 
effects of increased plasma levels of catecholamines (adrenaline and noradrenaline) and cortisol, 
hormonal messengers responsible for CV stimulatory effects in the context of organism’s adap-
tive responses to stress [13]. These effects are treated as a whole for preparing the body for fight 
and flight [14]. Besides these two major systems, in the neuroendocrine response of organism 
to stress, a number of other hormones are involved such as: thyroid’s hormones, antidiuretic 
hormone (ADH), aldosterone hormone, etc.
2.2.3. The immune response to stress
There is a bidirectional relationship, of mutual modulation, between the neuroendocrine and 
immune response to stress. It has been found that stress, both the cognitive (e.g., an emotional 
shock), recognized by the CNS, and the noncognitive (e.g., secondary to an infection, inflam-
mation) have the capacity to trigger a cascade of biological reactions that will directly or indi-
rectly involve the immune system. Thus, activation of the immune system is considered to be 
a noncognitive stressor using neural and neuroendocrine circuits identical to those that occur 
in cognitive stress. The immune response, both local and systemic, to stress may be one of the 
inhibitions (with anti-inflammatory action) in the context of eustress and one of the stimula-
tions (with pro-inflammatory action) in the context of distress. Two mechanisms underlie the 
immune response to stress: hormonal and nervous. In the hormonal mechanism, lympho-
cytes secrete pro-inflammatory cytokines type IL-1β, IL-6, TNF-α that activate both the HPA 
axis with consecutive hypersecretion of cortisol [15] and contribute to expression of receptors 
for cortisol and adrenaline with direct consequences in mediating innate and, respectively, 
acquired immune response; increased circulating levels of above mentioned cytokines IL-1β, 
IL-6, and IFNγ (interferon gamma) have been emphasized in depression [16]. Cytokine func-
tion in modulating the process of organisms adapting to stress and their direct relation with 
a series of neurotransmitters puts them nowadays in the spotlight, playing a key role in the 
body’s immune response to stress [17]. In the context of the nervous mechanism, the main role 
is played by the sympatho-adrenergic mechanism and stress neuropeptides with implications 
both in the periphery on lymph nodes, of the spleen, and thymus, but also centrally through 
CRH intervention that activates ANS, a situation that leads to summing the action of adrena-
line with cortisol and have as final effects the functional inhibition of the immune system.
3. The role of stress as a psychosocial factor in the plurifactorial  
etiology of CVD
Numerous studies have proven the role of psychosocial factors in increasing incidence of 
CVD and short- and long-term prognosis of patients with manifest CVD [18]. The impact of 
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psychosocial factors for both QOL and prognosis is becoming increasingly well defined in 
patients with heart failure (HF) [19], postcoronary bypass surgery [18], and implantation of a 
cardioverter defibrillator [20]. A distinction between psychosocial stress and psychosocial fac-
tors must be made. Defining the scientific concept of psychosocial stress implies the creation 
of a model for CVD (Figure 1) and its integration at various levels of all potential psychosocial 
factors involved in the development of these pathologies [21].
According to this model, it can be recognized by all experts that not only negative life events 
(financial loss, loss of partner, workplace, etc.), but also the negative emotions (depression, 
anxiety, fear, etc.) can become CV risk factors [18]. There is no official definition of psychoso-
cial stress. Thus, we can consider that the psychosocial stress model on the CV system is the 
released expression by the CV system itself to the action of psychosocial factors on it.
3.1. Mechanisms involving psychosocial stress in the pathogenesis of CVD and 
psychosomatic disorders induced by it on the heart level
Stress is an important part of our lives, essential in the short term, but it can become danger-
ous as a long-term presence. Mechanisms through which psychosocial factors can increase the 
risk of developing or worsening CVD are various and complex.
Figure 1. A stress model integrating psychosocial risk factors of CVD (after Ref. [21]).
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3.1.1. An unhealthy lifestyle
One first impact of long term of psychosocial stress is the individual’s recourse to an unhealthy 
lifestyle. Therefore, these patients smoke and drink more, often adopt an unhealthy diet, 
reduce their physical activity, etc., in comparison to the patients with no psychosocial factors 
[18]. Financial barriers of a high-quality healthcare are also contributing to an unfavorable 
prognosis, as after an acute myocardial infarction (MI), for example.
3.1.2. Pathophysiological changes
In CVD, participation of the psychosocial factor in both constitution and modulation of their 
evolution, together with other etiopathogenic factors is uneven, but it is proven by a series of 
experimental and epidemiological studies [22]. The leading role is the one of SNS hyperactivi-
ties (by disrupting the physiological balance between sympathetic and parasympathetic), being 
the body’s first defense mechanism that not only occurs both in acute conditions (requiring 
its rapid adaptation), but also in conditions of chronic persistence of stressor factors [23]. CV 
changes induced by the SNS hyperactivity during acute stress are represented by: short-term 
increase of blood pressure (BP) values, mediated through the activation of alpha-adrenergic 
receptors and heart rate (HR) by stimulating beta-adrenergic receptors, transient endothelial 
dysfunction, lowering the threshold for triggering the cardiac arrhythmias and increasing the 
risk of MI, left ventricular dysfunction, and even the sudden death [18, 24]. Under normal con-
ditions, the simultaneous growth of both the HR and the BP involves modulation of barore-
flex function. Particularly, under stress conditions, the sensitivity of baroreflex mechanisms is 
reduced, with loss of the major cardioprotective mechanism autonomic reflex [25], and finally, 
the persistence of this disorder favors the appearance of high BP. The risk of MI induced by 
psychological stress appears due to the simultaneous increase of both the systemic vascular 
resistance and the myocardial oxygen requirements, effects of the SNS stimulation, and con-
current discharge of catecholamines. Adaptive response of the CV system under stress condi-
tions occurs as a physiological response, but the generation alterations of autonomic impulses 
can trigger ventricular arrhythmias especially in the presence of a pre-existing CVD [21, 25].
A series of recent studies indicate that the asymmetrical brain activity plays an important role, 
too, in the heart vulnerability to ventricular arrhythmias, an aspect proven by the fact that the 
lateralization of brain activity during emotional stress may stimulate asymmetric heart, and 
by inhomogeneous repolarization which creates conditions of electrical instability that under-
lie the generation of ventricular arrhythmias [26]. It has been found that patients with CAD 
have this exaggerated asymmetric brain activity in several cortical areas during periods of 
psychosocial stress, such as the left parietal cortex, the left anterior cingulate, the right visual 
association cortex, the left fusiform gyrus, and the cerebellum [27].
The presence of the long-term stress creates favorable conditions for the persistence of arte-
rial hypertension (HT), initiation, and progression of the atherosclerotic vascular process [17] 
through both persistence at high levels of sympathetic tonus and as a result of its association 
with inflammatory process [17, 28] initiated by the elevated plasma levels of cortisol following 
the entry into action of the HPA axis [14, 28] and the development of resistance of the glucocor-
ticoid receptor [29], also due to activation of the sympathetic renin-angiotensin-aldosterone 
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system (RAA system). A number of behavioral disorders (increased appetite, sedentariness, 
and excess consumption of energy drinks) can be added, that the individual can acquire even 
some pathologies developed over a long period of stress, such as metabolic syndrome. The 
persistence of elevated BP beyond the moment of acute stress and its transformation into 
chronic stress conditions in a chronic pathology—arterial HT—are both due to the role the 
CNS plays in part through autonomic regulation of BP, hydro electrolytic balance, and ADH 
release [22], and entry into action of RAA system and the occurrence of inflammatory process 
at a vascular level, particularly the adaptive immune response that plays an important role 
in the pathogenesis of this disease [30]. It was initially revealed that experimental damage to 
certain regions of the brain like the anteroventral third ventricle, the subfornical organ, pre-
vents many forms of experimental HT [31], but recent studies have shown that these forebrain 
region plays an important role to peripheral activation of T cells and vascular inflammation 
during angiotensin II-dependent HT [32]. One of the principal pathways activating the RAA 
system is the SNS. Both, acute and chronic stress can increase renal renin levels and plasma 
levels of angiotensin II (ANG II) that acts to maintain the constant extracellular volume and 
BP by different mechanisms. High levels of renin and AGT II are attenuated by β-adrenergic 
blockade [33], thereby demonstrating the relationship between the two systems. The local 
renin-angiotensin systems (RASs) exist at the level of solid tissues (e.g., heart, kidney), but 
it is also present in the circulating RAS in a variety of circulating cells [34], and the ANG II 
type 1 receptors (AGTR1) are the most numerous expressed, and they mediate most of the 
known functions of ANG II [35]. Stimulation of these receptors, by increased plasma levels of 
AGT II, is responsible for the persistence of HT, pro-inflammatory, and pro-oxidative actions 
[35]. AGTR1 expression in all immune cells that were observed has contributed to involve-
ment of the RAS in vascular inflammation and the atherosclerotic process [35, 36]. According 
to the latest discoveries, both CNS and increased levels of ANG II and salt from the body 
are responsible for T-lymphocytes activation, which once activated, reached the peripheral 
blood vessels, and kidneys start the release of pro-inflammatory cytokines responsible for 
vasoconstriction and retention of sodium thereby contributing to the long-term maintenance 
of high BP values, respectively, arterial HT [31, 32, 36]. Reduction of the inflammatory process 
at the vascular level both through direct blocking of the production of ANG II by means of 
pharmacological agents like angiotensin converting enzyme inhibitors (ACE inhibitors) or 
indirectly by other pharmacological agents such us statins, is associated with the decrease 
of plasma levels of various pro-inflammatory and pro-coagulant markers from the old, high 
sensitive C-reactive protein, soluble cellular adhesion molecules of immunoglobulin family, 
the selectins group, up to long pentraxin 3, a new multimeric inflammatory biomarker, from 
the family of pentraxins that is nowadays one of the mechanisms of intervention in reducing 
BP values in hypertensive patients and reduction of the progression of the atherosclerotic 
process, issue proven by numerous clinical studies [37–39].
3.2. The psychosocial consequences of cardiovascular diseases
Psychosomatic disorders in CV patients are manifested through the appearance of psychi-
cal disorders echoing the suffering of the somatic, at the CV system level. Development of 
atheroma plaque both peripherally and at the cerebral level and also the decrease of cardiac 
output that has repercussions over the cerebral flow in patients with cardiac insufficiency can 
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induce the process of chronic cerebral hypoxia and is the cause of developing symptoms such 
as asthenia, fatigue, headache, and sleep disorders, in which over time can lead to diminished 
cognitive performance (attention, memory, and learning) and even ideational flow. A series of 
studies have pointed out that the cerebral vascular disease is associated with cognitive func-
tion and shows a key role in the decline of memory [40]. It has been found that 25–75% of the 
stroke patients can develop vascular cognitive impairment [40]. The development of carotid 
artery stenosis was associated with the decrease in neuropsychological performance due to 
the chronic drop of cerebral blood flow [40] and by affecting the neurovascular unit increases 
the likelihood for dementia [41]. It seems that both symptomatic and asymptomatic carotid 
stenoses are associated with cognitive impairment [42]. Withal, hypertensive individuals are 
more susceptible to developing cognitive impairments than those whose BP values are within 
normal limits [43]. Other cardiac conditions such as atrial fibrillation or HF, both reducing car-
diac output and increasing the risk for thromboembolism, have been associated by some, but 
not all, researches with cognitive decline [44, 45]. Frequently, the people with CAD develop 
illness-related symptoms in the recovery period, such as breathlessness and chest pain, both 
of which are associated with post-MI fatigue [46]. Majority of patients with heart disease 
from a hospital reported a poor quality of sleep and that subjective quality of sleep associated 
with fatigue post-MI and daytime dysfunction were predictors of depressive symptoms [47]. 
Among 15–20% of CV patients are depressed and as many of those who have suffered a heart 
attack later developed a major depressive relapse [48]. Approximately, 25% of patients with 
HF can develop a major depressive disorder and the share of depression symptoms among 
them can reach 30–50% [48]. CV patients acquire a special social status, starting from their 
removal from a number of stressful physical activities (household routine) to reduction or sus-
pension of practicing sports activities, hiking or even limiting sexual activity and ending with 
granting priority to emergency medical services. All these behavioral changes to which a car-
diac patient must suddenly undergo summed up with a number of other lifestyle restrictions 
concerning quitting smoking, alcohol, coffee intake, or the potential risk of relapse of acute MI 
are actually new sources of mental stress for him and culminate with the prospect of sudden 
death or possible long-term disabilities (physical, cognitive, emotional, and social) after stroke. 
Thus, the CV patient develops a state of fear and restlessness, of constant anxiety, as an expres-
sion of the presence of a continuous mental stress in one’s life with varying degrees of inten-
sity, playing an important and negative role in the development of one’s heart disease itself.
4. The implications of mental disorders in the pathogenesis of CVD
In recent decades, scientists began to increasingly focus their attention toward a group of 
nontraditional risk factors for CVD, also, including many psychosocial variables in their stud-
ies. The most studied issues are represented by the impact that negative emotions (e.g., anger, 
anxiety, and depression) have on the general health of the individual and further in initiat-
ing, precipitating, or worsening of pre-existing pathologies [18]. Although various negative 
emotions have been studied, the results of several researchers have led to similar conclusions 
regarding the impact of anxiety disorders and mood disorders which appear as two psychiat-
ric factors with a higher incidence among people with CVD [19, 48, 49].
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4.1. Depression and cardiovascular disease
Both experimental and epidemiological studies revealed a bidirectional association between 
depression and CVD. The changes in homeostatic and neuroendocrine function during the 
CVD create favorable conditions for the development of mood disorders, such as depression 
[47, 48], and depression, through behavioral and pathophysiological changes produced by 
it, is a recognized risk factor for CVD-related morbidity and mortality [48–51]. The major 
depression is the most common mood disorder frequently encountered among patients with 
CVD [52] and is the one that portends adverse CV outcomes and increased healthcare costs. 
The prevalence of depression is at least three times greater in patients with CAD or HF than in 
the general population, and one in five CV patients is depressed [48, 53]. If a series of depres-
sive symptoms are added to the major depression diagnosis itself (present but not enough 
to meet the diagnostic criteria), which frequently develop in a patient who recently suffered 
a heart attack, the share among these patients may increase at 40–65% [48]. The depressive 
symptoms developed by the CHD and HF patients are susceptible to contribute toward too 
limiting physical activity and impaired their QOL [53, 54]. Also the occurrence of depressive 
symptoms on the background of CVD is, as well, involved in both relapsed acute cardiac 
events (stroke, MI) and increased mortality [50]. Since the CV consequences of depressive 
symptoms continue to generate events with poor prognosis after acute coronary syndrome, 
the American Heart Association (AHA) issued a 2014 Scientific Statement recommending 
that depression be elevated to the status of a risk factor in acute coronary syndrome [55]. As 
regards to the relationship of depression with other CVD, such as arterial HT study, results 
are controversial [56].
Despite growing evidence of the close link between depression and CVD, the pathophysi-
ological mechanisms underlying these interconnections are still unclear. A series of the neu-
robiological processes and mediators that are common to both mood and CVD are considered 
to underlie this interconnection, consequence of their activation by psychosocial stress. These 
include the following behavioral and pathophysiological mechanisms: (a) neuroendocrine 
and neurohumoral changes involving dysfunction of the HPA axis and consecutive activation 
of the RAA system; (b) immune system alterations including activation of pro-inflammatory 
cytokines; (c) autonomic and CV dysregulation, which include increasing the sympathetic 
activity, decreasing the parasympathetic tone, HR and rhythm disturbances, and altered 
baroreceptor reflex function; (d) central neurotransmitter system dysfunction including dopa-
mine, noradrenaline, and serotonin; and (e) behavioral changes including fatigue and physi-
cal inactivity [57].
More and more studies have emphasized the connection between depression and ANS and 
CNS dysfunction. The response of the HPA axis and consecutive activation of the RAA sys-
tem are similar to the body’s physiological responses to stress factors and has been linked 
directly or indirectly to CV regulation and endocrine changes associated with depression 
[57, 58]. Dysfunction of the HPA axis was described for the first time by Carroll [59, 60] and 
the functional consequences at its different levels translate into alterations in the release of 
CRF, dysregulated adrenocorticotropic hormone (ACTH) (response to CRF’s alterations), and 
elevated circulating cortisol or cortisone levels [61], which have been observed at the depres-
sive patient in the cerebrospinal fluid, hypothalamus, and locus coeruleus [62]. Damage of 
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the hippocampus caused by stress seems to be the key of the dysregulation of the CNS and 
is responsible for the depressive symptoms, through its consequences generated on HPA 
axis’ activity [63]. Endocrine and immune systems interact with each other and some of their 
functional disorders are common to mood disorders and CV disease, playing a role in the 
combination of the two pathologies. In 1991, Smith was the first to propose the macrophage 
theory, the pathophysiological mechanism of dysfunction of the immune system associated 
with depression, as a result of an excessive secretion of monokines such as interleukin (IL)-1, 
tumor necrosis factor (TNF)-α, and interferon [64, 65]. Similar pro-inflammatory cytokines 
such as TNF-α, IL-1β, and IL-6 are released into the systemic circulation of post-MI patients, 
demonstrating an activation of the immune system that is directly linked to specific CVD 
[16, 65, 66]. Once synthesized, they have negative consequences in both the CV and CNS 
[66], thus being responsible for occurrences of not only depression symptoms but also neu-
roendocrine and autonomic systems disorders. Also, peripheral cytokines play an important 
role in the release and metabolism of several CNS neurotransmitters, including monoamine 
neurotransmitter (dopamine, noradrenaline, and serotonin) [67], alter the glucocorticoid axis 
and increasing the plasma levels of cortisol [68], aspects directly related to the onset of clini-
cal depression [69]. A different mechanism underlying the link between depression and CVD 
is that of the combination of hypercortisolemia and platelet function disorders, including 
enhanced platelet reactivity and release of different platelet products [61, 70], one can say that 
it creates the theoretical foundations that explain the pro-atherosclerosis effects of depres-
sion. An interesting aspect is represented by the increased levels and reactivity of platelets 
that has been associated with the presence of depression among both healthy individuals and 
patients with CVD [70]. Possibly this quantitative and qualitative exaggerated response of the 
platelets could be responsible for the connection between depression and CVD [71]. An influ-
ence of depression in reducing HR variability and baroreflex cardiac control in CAD patients 
[72], and impaired coronary flow reserve that increases risk of acute coronary syndromes 
have also been observed. All these mechanisms suggest that patients with depression have an 
increased risk of developing heart rhythm disorders. Recent studies results have revealed that 
behind these complex interactions between depression and CVD is a genetic predisposition, 
further research focused on identifying specific genes that link depression/negative affect 
and CVD. It was thus determined that the serotonin transporter (SERT) gene polymorphism 
plays an important role in both pathologies [73]. Under the behavioral aspect, depression is 
associated with decreased adherence to recommended risk-reducing behaviors for different 
chronic diseases, including CVD [74], diabetes mellitus, etc. For instance, the development of 
depressive symptoms in patients with CAD has been associated with decreased adherence 
to taking CV medications, attending cardiac rehabilitation, quit smoking, physical activity, 
and modified diet [75]. Many studies suggest that the poor adherence to these recommended 
behaviors is the link between depression and increased mortality in patients, after MI and 
poor prognosis in general for the CV patient [74, 76].
4.2. The association between anxiety disorders and cardiovascular diseases
A series of study results suggest that anxiety, too, plays an important role in prognosis of 
coronary heart disease (CHD) patients independent of depression [18, 19, 49, 52, 77], but there 
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are still many unclear aspects regarding its role as an etiologic factor in the pathogenesis of 
CVD. The main issue derives from the fact that it is difficult to establish a certain diagno-
sis of anxiety disease with a CV patient, because many symptoms characteristic of a panic 
attack (one form of manifestation of anxiety disease) overlap with the clinical symptoms of 
CHD, and in these circumstances, it becomes difficult to make a differential diagnosis [77]. 
A meta-analysis was carried out by Roest et al., assessing the association of anxiety disorder 
with risk of CHD [78]. Their results showed that anxiety seemed to be an independent risk 
factor for incident CHD and cardiac mortality, independent of sociodemographic variables, 
biological risk factors, and health behaviors. Anxiety takes different forms in relation to the 
types of CVD. For example, a patient with atrial fibrillation does not particularly associate 
symptoms of anxiety, but worry and phobic anxiety have the highest rate of association with 
CHD [79] and posttraumatic stress disorders are frequently linked with risk of stroke and 
CHD [80]. Most studies have revealed a close link between anxiety disease and CHD. The 
mechanisms proposed to underlie this link are represented by the fact that anxiety was asso-
ciated with a higher risk of developing the ventricular arrhythmias, as a consequence of HR 
variability after MI [81], and a progression of atherosclerosis [82]. Also, anxiety is associated 
with an unhealthy lifestyle in patients at risk of CHD [75], such as excess of cigarette smok-
ing or alcohol consumption, lower physical activity, and poor adherence to CV medications 
[74], which increase the risk of CVD. Pathophysiological mechanisms’ model proposed for 
anxiety’s intervention in the pathogenesis of CVD is the one for accumulation of anxiety as 
a chronic stressor factor along with other negative emotions and its intervention at the level 
of the two systems: ANS and CNS with the activation of the HPA axis and increased release 
of plasma catecholamines, and endothelial damage, underlying the initiation and progres-
sion of atherosclerosis and development the CAD (also known as CHD), and acute coronary 
events. If this model is viable, it may be expected that anxiety would be frequently associ-
ated with increased BP. However, in medical practice study, results are controversial. There 
is a link between anxiety and HT, but anxiety as a risk factor for incident HT is unclear [83]. 
Another model which could explain the conflicting results of various epidemiological studies 
is represented by the emotional triggering model in which the individual’s timing of anxiety 
measurement is essential [84]. Acute anxiety is often associated with hyperreactivity of the 
CV system to stress [18]. The close connection between anxiety, CVD, and sudden death, 
suggests that ventricular arrhythmias may be the principal mechanism for cardiac death. The 
pathophysiological mechanism that underlies this hypothesis is the reduced HR variability 
by increased SNS stimulation or impaired vagal control [85]. It was also revealed that anxiety 
alone is associated with higher platelet levels [71], and co-occurring with depression, when 
the two comorbidities have the highest platelet levels [86], increases the risk of acute events in 
CAD patients. The direct effects of the SNS together with the activation of HPA axis increase 
the risk of developing a CVD and lowering the threshold for myocardial ischemia, arrhyth-
mias, and sudden cardiac death in patients with symptoms associated with anxiety [79, 81].
4.3. The importance of personality type
An important role in increasing the risk of CVD is apparently played by the individual’s 
personality type. Thus, two kinds of personality Type A and Type D have been related to 
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increased risk of CVD. Initial studies have revealed that personality Type A, characterized by 
hostility, ambition, competitiveness, etc., is more prone to CVD [87]. However, subsequent 
studies have reported that the association between Type A behavior and the risk of develop-
ing the CVD is insignificant or reduced to a limited number of cases [87]. In recent years, 
attention was also directed on the Type D personality, which is characterized by a combina-
tion of negative affectivity and social inhibition. This individual accumulates high levels of 
chronic distress that are not recognized by him and, therefore, are not to be expressed. The 
patients with CAD and Type D personality profile have associated a risk almost 2–2.5 times 
higher for developing adverse cardiac events [88] and in this association, Type D personality 
appears to be an independent risk factor for CVD.
4.4. Pharmacological implications during depression, anxiety, and CVD treatment
Regarding depression, its prevalence among patients with CVD is high (20–25%), both the 
immediate and the long-term prognosis of a CV patient worsens 2.2 times if one develops 
depression, but there is also a controversy about the use of antidepressants, selective sero-
tonin reuptake inhibitors (SSRIs), in particular, whether or not it increases the risk [89]. As 
follows, antidepressant medication is among the most frequently prescribed medication in 
the world, and its consumption has skyrocketed in the last decade [90]. However, information 
concerning antidepressants’ relationship with CAD is rather less known. Numerous stud-
ies have highlighted an increased risk of CHD during use of antidepressants, especially in 
tricyclic antidepressants [91]; reports have also emerged in this regard for patients who are 
users of SSRIs [92]. From a theoretical perspective, antidepressants such as SSRIs (which have 
potent antiplatelet activities) should have good effects in terms of coagulation. Tri- and tet-
racyclic antidepressants should not be used for the pharmacotherapy of patients with CVD 
associated with depression too [91], because by increasing the concentration of monoamines 
in the synaptic space can have multiple CV side effects by increased catecholamine activ-
ity on adrenergic and serotoninergic receptors. Therapy with monoamine oxidase inhibitors 
(IMAO) is contraindicated in CV patients, as antidepressants are, because they irreversibly 
or reversibly inactivate the enzyme monoamine oxidase and increase concentrations of the 
noradrenaline in the synaptic space, leading once more to CV stimulation [91]. The US Food 
and Drug Administration (FDA) issued in 2011 a drug safety communication regarding cita-
lopram (SSRIs) administration not to exceed the dose of 40 mg/day, based on study findings 
of QT interval prolongation, with different doses of citalopram [93]. A similar warning was 
also issued by the European Medicines Agency in 2011. QT interval prolongation is a favoring 
condition for development of arrhythmias including potentially fatal torsades de pointes [94], 
issue that has also been recognized with other antidepressants such as escitalopram and ami-
triptyline [94]. Old age along with other factors such as female gender, family/personal history 
or concomitant use of drugs with a potential for QT interval prolongation, increase the risk of 
cardiac toxicity of SSRIs antidepressants particularly in conditions of overcoming the thera-
peutic plasma concentrations [95]. Sertraline, a SSRIs molecule with a favorable cardiac-safety 
profile, is still considered a safe and effective treatment for recurrent depression in patients 
with recent myocardial infarction or unstable angina [96]. Because stress and anxiety disor-
ders are prevalent in patients with CVD, in coronary care units, the use of the benzodiazepines 
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as anxiolytics drugs is reasonable [78]. The benzodiazepines are considered as one of the saf-
est groups of drugs in patients with CVD, because they are free of adverse cardiac effects and 
can be safely used by them even in the coming period after MI. A number of CV medications 
can, in their turn, exert neuropsychiatric influences with the consequences on the affect and 
physical status of an individual. The link between the use of β-adrenergic blocker agents and 
neuropsychiatric consequences, especially fatigue and depression, has long been described 
[97]. Many case reports and several small reviews support the link between propranolol and 
depression and, also, the increase in the number of antidepressant prescriptions in patients 
under treatment with propranolol supports this point [98]. A recent study has highlighted 
that all antihypertensive agents in monotherapy used in arterial HT treatment were associ-
ated with symptoms of depression, anxiety, or both [99]. Only the intensity of effects on mood 
is differentiated from one class of antihypertensive agents to another: β-blockers and calcium 
antagonists may be associated with increased risk, whereas ACE inhibitors and sartans may 
be associated with a decreased risk of mood disorders [100]. Fatigue alone or in combina-
tion with sedation occurs with greater frequency than placebo during therapy with calcium 
channel blockers, without requiring dose reduction. Diuretics may produce neuropsychiatric 
symptoms mainly indirectly, through electrolyte disorders or vitamin deficiencies (the loop 
diuretics-associated with thiamine deficiency), but are not frequently associated with fatigue, 
sedation, or cognitive impairment [101]. During the treatment with methyldopa, Paykel et al. 
found that sedation occurs in approximately 30–35% of the patients associated with marked 
fatigue and other studies reported a cognitive impairment [101], both through direct action of 
methyldopa or following sedation and translated by impaired concentration and decreased 
cognitive performance. Digoxin, used in the treatment of congestive HF (secondary after MI 
or other CVD) and as a rate control drug for atrial fibrillation and atrial flutter, can also have 
considerable central actions and has been shown to induce a variety of neuropsychiatric side 
effects, both at therapeutic levels and in toxicity, as: fatigue, depression, “mental disturbance” 
in 5% of patients taking this tonicardiac drug [102], psychosis, and delirium.
5. Behavioral aspects of the cardiovascular patient during his illness
In case of psychosomatic diseases, category that includes CVD, in which the psychological 
factors play an important role in their triggering or worsening, numerous studies have high-
lighted that cognitive representation of illness is a significant predictor of patient’s recovery 
and social reintegration and indirectly through its consequences is reflected on the quality 
of one’s life. Also, studies have shown that individuals can directly influence the results of 
different interventions on their health, both positive and negative, depending on the mental 
representation of the illness. The cognitive model of the illness (valid for all psychosomatic 
illnesses) was created by Leventhal et al. [103] and structures the beliefs of the individual 
about illness in five dimensions, represented by: identity (name and all signs and symptoms 
of the disease); cause (perception of possible triggers of the disease); time-line (perception 
about how long the illness might last and how will it evolve); consequences (perception of 
effects of the illness in the physical, social, emotional, and economic levels); and curability 
and controllability (perception of the degree to which the disease is curable and manageable). 
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This model that best explains the relationship between the illness perceptions and emotional 
and behavioral responses is called the self-regulatory model, and this process is performed 
through three stages of interpretation, coping, and appraisal. The patients’ cognitive rep-
resentations and perceptions model of their illness, proposed by Leventhal et al. [103], are 
known to influence patients’ motivation to engage in preventive behavior, or curative healthy 
behavior with healthy outcomes, all expressed in health-related quality of life (HRQOL). This 
model explains that based on the individual cognitive and emotional perceptions about the 
illness, the individual reacts to various internal and external stimuli and generates illness-
related cognitive and emotional representations that will be the basis of one’s decisions on 
adaptation strategies in the new context of the disease.
5.1. Patients’ quality of life
CVD in general and CAD in particular are nowadays the major cause of premature death in 
Europe [1] and also an important cause of morbidity, contributing substantially to increasing 
healthcare costs. It is a known fact that health services around the world are more oriented 
toward improving the quality of patient care than toward prevention measures, and acute 
care programs are more common than chronic care programs. For these reasons, WHO in 
The European Health Report from 2015 sets as its main objective the reduction of prema-
ture mortality from CVD, cancer, diabetes mellitus, and chronic respiratory diseases by 1.5% 
annually, until 2020 [104]. By adopting a Health 2020 Monitoring Framework Program in 2012 
as the new European health policy framework, member states mandated the WHO Regional 
Office for Europe to measure and report on the well-being of the European population as a 
tool to measure health improvement of the European population. The Murray & Lopez study 
regarding plausible projections of future mortality and disability between 1990 and 2020 [105] 
highlighted that the leading causes of disability-adjusted life years predicted by the baseline 
model were (in descending order): ischemic heart disease, unipolar disorder/major depres-
sion, and cerebrovascular disease—three pathologies out of total top four of their results. 
Both, acute and chronic cardiac illnesses are widely recognized to have a negative impact on 
patient’s QOL. Patrick and Erickson define HRQOL as “the value assigned to duration of life, 
as the patient’s subjective perception about the impact of disease, injury, treatment or policy 
on their everyday life through the impact on physical, functional, and emotional status” [106].
Essential HT is one of the main risk factors of CVD, and at the same time, one of the main 
causes of death from noncommunicable diseases, still remaining a public health problem 
despite early diagnosis and the therapeutic advances in recent years. Undiagnosed and 
untreated or poorly monitored and treated diseases cause a number of CV complications: 
from CAD to HF, ischemic stroke, etc., with the impact on family, social, and professional 
life of patients and implicitly on their HRQOL. Many aspects of the relationship between 
HT and QOL are still unclear and unsolved. The impact of psychological disorders such as 
depression and anxiety on CV health is well known and studied by the scientific community, 
but the relationship of these two comorbidities with arterial HT is still controversial and not 
well understood [56, 83]. Results of a 2010 study emphasized that both comorbidities sig-
nificantly associate with essential HT, depression more than anxiety, indeed, and that this 
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association had a significant effect on hypertensive patients’ worsened QOL [107]. Awareness 
of their hypertensive status was highlighted as another factor that can exert influence on the 
hypertensive patients’ QOL. According to the results of some studies, awareness of HT was 
negatively correlated to HRQOL in hypertensive patients [108] and the methods of modify-
ing the attitudes of the hypertensive patient facing illness (from a passive to an active and 
positive one) have shown that a positive active attitude is an important element of self-effi-
cacy, which is the most important component of social cognitive theory [109]. Self-efficacy 
requires motivating the patient to perform their duties and obligations deriving from their 
new condition, especially the chronically ill, in this case, the CV chronic conditions in order 
to produce the desired results that will lead to improvements in health-related behaviors and 
medication compliance. We can say, starting from Leventhal’s self-regulatory model, that the 
change (in a negative or positive sense) of cognitive perception of the disease on the mental 
level of the patient with chronic cardiac condition will help address the patient’s reaction to 
this disease, respectively, increasing self-efficacy expressed by improving HRQOL and cost 
reduction in health insurance systems. The poor QOL of treated hypertensive patients seems 
to be attributed to a more intensive drug treatment for controlling BP and changes in lifestyle, 
also, issues that may negatively impact on HRQOL [110], but this association was not attrib-
uted to adverse effects of BP-lowering drugs or any particular class. Analyzing the impact of 
association of various comorbidities with the appropriate drug therapy and high BP, it has 
been observed that the number of comorbidities does not significantly affect the hypertensive 
patient’s QOL; however, the number of drugs exerts significant influences on different aspects 
in their QOL [111]. This issue could be explained by negative perceptions of patients about a 
large number of co-prescribed drugs as a result of poly pathologies, perception that entails a 
low adherence to antihypertensive treatment. All this suggests that awareness of being sick 
and not the disease itself, the need to respect a medical treatment for life, changes in lifestyle 
that impose restrictions on smoking, alcohol consumption, physical activity limitation, etc., 
are reasons for lower QOL of the hypertensive patient.
CAD is one of these chronic CVDs characterized by impaired functional capacity and quality 
of life. QOL of patients with CAD is influenced by a number of risk factors among which the 
most important are represented by depression, anxiety, and other associated comorbidities. 
Study results from the last decade revealed a prevalence of depression among 10–40% of the 
patients with CAD [50, 52, 53]. Since depression is both a primary and secondary risk factor 
in the development of morbidity and mortality in patients with CAD, independent of tradi-
tional risk factors such as smoking, HT, atherosclerosis, the new guidelines recommend a 
psychological profile screening of these patients for early detection of the tendency to develop 
depression [55, 112]. Among these patients, the results of various studies have highlighted that 
depression is strongly related to the presence of angina [49], and angina severity is directly 
related to their QOL. An interesting aspect is the fact that self-reporting on the perception of 
cardiac health status is independently predictive of long-term mortality in those with CAD 
[78]. Depressed patients with CAD vs. nondepressive reported a wider cognitive perception of 
the illness’ burden [53]. Anxiety is another psychological state whose relationship with CAD 
was analyzed in a smaller number of studies, and it has been observed that its share in those 
patients was approximately 36% [78, 79]. The impact of CAD on the HRQOL differs according 
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to gender too; thus in women an unfavorable impact is reported in contrast to men [113]. But 
other factors may influence the QOL of CAD patients such as age, physical limitation due to 
angina, and angina frequency has an impact on prognosis as well as on HRQOL. Potential 
unfavorable prognosis of patients with CAD (at risk of developing MI, unstable angina, 
cardiac arrhythmias, etc.,) has a strong negative impact on the emotional component of the 
QOL assessment questionnaire, issue supported by the results of clinical studies highlighting 
the frequent association of depression and anxiety disorder with CAD. The patient’s physi-
cal function component is also impaired in patients with CAD, but its intervention is in the 
background of QOL. The fact is that by summing up the consequences of both components, 
emotional and physical activity, CAD has a significant negative impact on the HRQOL of 
these patients. According to new discoveries, the healthcare professionals have an obligation 
to recognize, identify, and treat these variables that interfere with maximizing the benefits 
of cardiac surgery and pharmacological interventions aiming to improve a patient’s physi-
cal QOL. The public health interventions, such as cardiac rehabilitation programs promot-
ing physical activity, changes in diet, and quitting smoking are nowadays the main methods 
to improve CAD outcomes and their benefits are recognized today. These programs should 
improve perceived health status in the CAD population, especially in women. It is gener-
ally agreed today that benefits and risks of different therapeutic strategies of the underlying 
disease must be viewed from the individual perspective of the patient, an aspect known as 
personalized therapy. These principles underlie the concept of the “person-centered care,” a 
concept with dynamic development in the CVD management sector in particular [114].
A large number of studies have tracked the impact of HF on HRQOL, given the fact that it is 
a disorder with consequences for all assessment dimensions of QOL, and this quality altera-
tion of life reflects back on HF further contributing to increasing its severity. HF is a condi-
tion with a large share in the general population, particularly in the aged population, with 
a prevalence of up to 12%, with high financial costs, high mortality that reaches 50% in the 
5 years following diagnosis, and frequent hospital admission [115]. HF has become today a 
major public health problem worldwide because of its incidence, prevalence, and evolution-
ary prognosis. The impact of HF on the functional component of QOL appears to be the most 
important and with the most severe consequences, aspect highlighted by the EPICAL study 
specifying that a QOL score reduction by 10 points is associated with a 25–35% increase of 
death rate and hospitalization for HF [116]. Limiting physical activity will hinder the patient’s 
participation in a number of social activities that will restrict its network of social support, 
the patient becoming increasingly dependent on his family, leading to the development of a 
sense of burden for them. In this phase, the emotional component is added to deterioration in 
the QOL; patients face an increasing risk of developing anxiety and/or depression symptoms 
due to anxiety generated by fear of occurrence of decompensation moments and even sud-
den death, which further limits the autonomy and their activities [51, 53]. Anxiety symptoms 
are frequently reported by patients with HF, and these patients have a much higher anxiety 
level than healthy older adults. It has been found that patients with chronic HF and depres-
sive symptoms (which account for 30–50% among them) have a significantly increased risk of 
death, repeated hospitalizations, and worsened HRQOL [53, 54]. The association of anxiety 
Well-being and Quality of Life - Medical Perspective94
and depression symptoms was observed in approximately 30–35% of patients with HF, an 
association that increases the risk for both reductions in QOL concerning health [117] and 
shortening of the survival rate. Taking into consideration that patients with HF show a high 
prevalence of physical symptoms, including dyspnea and fatigue, and more than 30% of these 
patients also have depressive symptoms [48], both with consequences for the subsequent evo-
lution of the disease and also on the HRQOL of these patients. Heo et al. [118] investigated if 
a relationship between the two variables exists and found that physical and depressive symp-
toms have a dose-response relationship with HRQOL. Perception of loss of control exercised 
by these patients over variables such as physical and depressive symptoms and functional 
status seem to play an important role, hindering their improvement, an aspect that leads to 
considerable deterioration of their QOL [119]. Family support offered to patients with chronic 
illness seems to play an important role, too, in general and in particular in this case in relation 
to chronic HF patients’ QOL. Family support must provide encouragement, empathy, and 
increase feelings of trust of the patient’s own resources to regain their autonomy previous to 
the disease. Depending on the success of changing these perceptions about their disease, the 
HF patient may recourse to modification of behavioral self-regulatory model of Leventhal, 
and so these patients can engage in their care regime, choose whether to adhere or not to 
their prescribed regimen, thus becoming an active part of patient-centered care programs in 
order to improve health-related quality of their life, reduce hospitalization rate, and costs in 
the healthcare system and not least the reduced death rate. All these observations of previ-
ous studies support the view that better relationships between patient’s perspective on fam-
ily functioning, greater autonomy support, lower family criticism, and greater knowledge of 
family members and HF patients are associated with lower levels of depressive symptoms 
and better HRQOL, aspects proven by results obtained from the analysis of the impact of 
these factors by Stamp et al. [120]. Complex drug therapy that requires daily administration, 
also, presents increased risks of adverse effects and interactions that implicitly call for care-
ful biological monitoring, respectively, increased cost, and is an added stress factor for this 
patient. All this calls for greater economic and social resources from the chronic HF patient, 
and their absence, especially in the elderly, may be related to HRQOL, rehospitalization, and 
high mortality. The new behavioral changes (dietary salt restriction, weight control, regular 
physical activity, self-monitoring of symptoms, etc.,) are part of nonpharmacological treat-
ment of these patients and also have an impact on their QOL and entourage.
Of all the previously presented psychosocial factors, being in a stronger or a weaker rela-
tionship associated with deterioration of the QOL of the patient with CVD, depression has 
received the most attention from researchers in the last decade. The results of these stud-
ies have brought a clear evidence of depression association with CVD which is why recent 
clinical recommendations include mandatory screening for depression and its treatment, as a 
standard of efficient care of these patients [112].
It is already well known that the type D personality, which is a combination of two char-
acteristics, namely negative affectivity and social inhibition, is associated with an increased 
incidence and risk of mortality due to CVD [88], and only few studies indicate that type D 
personality is associated with QOL both in health and in disease [121]. Type D personality 
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is considered an independent predictor of CV morbidity and mortality, the worsening QOL 
in patients with CAD and HF [122]. Type D personality becomes a pre-morbid condition for 
affective disorders especially among CV patients and hence the consequences in their HRQOL.
5.2. Therapeutic adherence in cardiovascular disease
Analyzing worldwide data on the global burden of disease, it can be observed that HT ranks 
first, before smoking and obesity: 26.4% of world adult population had HT in 2000, and its 
incidence is expected to reach 29.2% in 2025 [123]. Furthermore, today one of the major causes 
of mortality in the world is the CVD, which is expected to be the world’s leading cause of death 
in 2020, the CHD being the first among them [124]. The high BP level is the most important 
modifiable risk factor of CVD, but despite the large number of potent antihypertensive drugs 
they succeed in achieving an optimal control of BP values only in 50–66% of patients [125, 126]. 
One possible reason for this low rate of BP control is that the antihypertensive medication is 
not taken as prescribed or not taken at all by the vast majority of patients [127]. In other words, 
the simple nonadherence to existing CV medication becomes a new risk factor for CVD. In the 
current context, the main objective of WHO in the 2015 European Health Report is to reduce 
premature mortality by CVD, cancer, diabetes mellitus, and chronic respiratory diseases by 
2020 [104] due to the fact that chronic diseases generate high costs in the health insurance 
system and affect HRQOL, and they require providing services for their better management. 
Among the many factors that can increase the effectiveness and efficiency of these services, 
patients’ treatment adherence and compliance to medication play an increasingly important 
role today, counseling patients is the main objective of the new policy in health for 2025 [128].
5.2.1. Adherence to medication and illness perceptions
Nowadays, in a broader sense, the concept of therapeutic adherence stands for the extent to 
which a person’s behavior regarding the use of prescribed medication, respecting a diet, and/
or a lifestyle change (reducing salt intake, stopping smoking, weight loss, etc.,) correspond 
to the therapist’s recommendations [129]. This newly introduced term in medical practice 
tends to replace the previous term of therapeutic compliance that has its origin in physics, 
given that the latter transmits an authoritative message from medical and pharmaceutical 
staff, which implies a passive attitude, of subjecting the patient to therapist decisions and 
failure of noncompliance can be seen from this perspective being only the fault of the patient. 
The adhesion term also includes the patient in making decisions about the treatment of his 
own disease, by establishing a partnership between the patient and the specialist, where the 
patient is a direct, active, and responsible partner on the results of his own treatment, thus 
becoming a major player in one’s disease management [129]. Compliance can be defined as 
“taking medications as prescribed” [130] and involves an understanding of the correct use of 
medication and a positive attitude of the patient facing treatment due to a perceived personal 
benefit from its application. Therefore, patient compliance to treatment is mirrored in the 
individual’s health and QOL.
Regarding arterial HT, clinical practice reveals that around 16–55% of hypertensive patients 
give up treatment during the first year of diagnosis and initiation of appropriate therapy of 
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the disease. Because many patients are reluctant to voluntarily provide information on their 
adherence to antihypertensive treatment, the true rate of nonadherence to medication may be 
even higher. Nonadherence to antihypertensive therapy is responsible for poor treatment out-
comes or treatment failure, finally determining an increase in the rate of hospitalization and 
thus impairment of their medication-therapy-related QOL [131]. A number of studies have 
shown that various factors, such as demographic, clinical, treatment related, or behavioral, 
are responsible for adherence/nonadherence of antihypertensive medication, but in older 
adults, a major role seems to be played by psychosocial factors [132]. A study conducted in 
the USA highlighted that including a decline in physical and mental quality of the individual, 
as components for assessing QOL among hypertensive elderly people, is associated with lack 
of adherence to medication [133]. The results of numerous studies certify that an increased BP 
controlled by antihypertensive medication can at the same time improve HRQOL for these 
patients, reduce the risk of complications, and repeated hospitalizations of the hypertensive 
patients. A systematic 2016 review analyzing the relationship between QOL and treatment 
adherence in hypertensive patients certainly emphasizes: “nonpharmacological treatment 
improves the overall QOL and physical domain of people with arterial HT and adherence 
to pharmacological treatment has a positive impact on the mental and physical domains of 
patients, as it did on the overall QOL score” [134]. As predictors of nonadherence to antihy-
pertensive medication, the following factors have been identified: poor knowledge of com-
plications of HT, unavailability of antihypertensive drugs in the healthcare facilities, lack of 
education of hypertensive patients in the healthcare facilities, prior experience of medica-
tion side effects, uncontrolled BP, and taking nonprescribed medications (as self-medication) 
[135]. Another aspect of adhesion is the persistence of the treatment of patients. In case of HT, 
it has been observed that tolerance and self-perception that the adverse effects of antihyper-
tensive medications play an important role in the patient’s motivation to follow this treat-
ment for the rest of his lives [136]. Thus, hypertensive patient’s adherence and persistence to 
pharmacological and nonpharmacological treatment is a key component of HT management.
Despite advances in the field of CV pharmacology and interventional cardiology that contrib-
uted to increasing the rate of survival after heart attack, CAD remains worldwide an impor-
tant cause of morbidity and mortality [137]. In this context, attention and efforts of specialists, 
in this pathology, must be directed toward secondary prevention, prevention that involves 
better management of both lifestyle factors and physiologic parameters, most often with 
medications. Although the number of prescriptions for CV medications among these patients 
increased significantly in the last 20 years [138], a large percentage fail to meet therapeutic 
goals aspect highlighted by the results of the European Action on Secondary and Primary 
Prevention by Intervention to Reduce Events III (EUROASPIRE III) survey [139]. Therefore, 
the main issue that was raised in this study was if the patient with CAD is compliant with 
medical therapy or not [140], an aspect appears to be closely related with a paternal clinician-
patient relationship and not of the partnership.
The CV medications, according to clinical evidence, are now responsible for more than 40% 
reduction in mortality in CAD, and premature discontinuation, willingly by the patient, of 
some classes as beta blockers, antiplatelet agents, or lipid-lowering drugs [141] have shown 
unfavorable outcomes on morbidity, mortality, and HRQOL of these patients. A supply of 
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more information specific to pharmacological treatment (e.g., the consequences of nonobser-
vance or sudden withdrawal of treatment) when initiating therapy improving the transition 
between secondary and primary care and a better explanation of the risk of relapse and the 
development of other possible complications of the disease, may contribute to attitude and 
behavior changes toward better patient treatment adherence. Under conditions in which HF 
is characterized by a high rate of hospitalization and has a negative impact on physical activ-
ity and on HRQOL, with high mortality, taking CV medications is essential to control HF 
symptoms and prevent exacerbations. The low adherence to HF pharmacological and non-
pharmacological treatment (physical activity, diet modification, and weight control) increases 
mortality, morbidity, hospitalization rates, and healthcare costs. The negative affectivity and 
social inhibition, type D personality characteristic features, which are associated with poor 
health, a greater number of cardiac symptoms, impaired physical and mental health are 
known predictor factors of nonadherence to prescribed medication regimens, and if encoun-
tered among patients with HF, it translates into a poorer adherence to medication, which may 
lead to adverse health outcomes implicitly and QOL [142]. It seems that an important role in 
mediating the relationship between type D personality and adherence to medication is played 
by medication self-efficacy. Self-efficacy or personal efficacy, which is defined as confidence 
of the individual in their own ability to complete tasks and achieve objectives [143], seems to 
be associated with medication adherence, thus being an intermediate measure for health out-
comes among HF patients. Low levels of self-efficacy have been associated with poor self-care 
adherence in patients with HF, and a better medication adherence was observed after improv-
ing self-efficacy to medication for type D patients with HF [144]. Therefore, the chronic HF 
becomes the most frequent diagnosis of hospital discharge, of all chronic conditions, generat-
ing a medical and psychological burden that impacts on HRQOL of those patients and eco-
nomic burden on national healthcare systems. Improvement of their outpatient management 
by good-quality primary healthcare services becomes a necessity and can only be achieved 
when the two partners, specialist and patient, establish a partnership and understand that a 
treatment has more benefits than risks or costs, in other words, a strong degree of therapeuti-
cal adherence is essential by developing and applying interventions to enhance medication 
self-efficacy.
Another general problem of nonadherence is the so-called profligate patients, that is, those 
patients to whom medication was prescribed but is never followed in the long term. It has been 
found that more than 20% of prescriptions are never picked up from the pharmacy (given the 
high cost of medication, patient acceptance of the new status, etc.,), others 20% are honored 
although used incorrectly (errors in dosage, rhythm by omitting doses, etc.,) or are not con-
sumed in 50% of cases by patient-initiated drug holidays [145]. Nonadherence to treatment 
appears to be the result of patients’ decision, more or less thought-out, and translated by a 
change in the behavior toward their health, following a partial compliance or an infringement 
of the healthcare practitioners’ guidance on therapeutic recommendations. Nonadherence is 
a complex phenomenon that is characterized mainly by two concepts tightly connected to 
each other: adherence (denoting the level of patient taking his medication and respecting 
the indications of healthcare practitioners regarding self-monitoring treatment and periodi-
cal controls) and persistence (denoting the time in complying with medication consumption) 
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[129, 131]. Medication adherence is thus a crucial self-care behavior for all the patients with 
chronic disease and especially for the CV patients. For these reasons, all needed efforts are 
made to develop predictive models for screening to better identify prospective patients at risk 
of nonadherence to treatment [146].
Leventhal’s self-regulatory model is the basic explanatory model of patient adherence to treat-
ment [147]. According to this model, when people try to understand the unfortunate event 
that suddenly appeared in their lives, sometimes with permanent consequences on personal 
and family life, they develop their own model at the mental level of its individual perception 
which brings together the five key components: what is the disease; what are its underlying 
factors; what are its consequences in everyday life; the time duration of disease and not least if 
they can cure or control it [147]. The uniqueness of illness representation derives from the fact 
that it is originated in the person’s own intrinsic beliefs, they do not necessarily comply with 
scientific arguments and is in a permanent dynamics, suffering a series of changes, depending 
on the age and sex of the patient, the disease and one’s experiences throughout it [147]. On 
the basis of their illness representations, patients subsequently develop their own response 
and coping strategies in order to adjust or minimize the impact of disease on the health of 
their own organism. Patients’ decision to become adherent to medication is one of the health-
related coping strategies. An individual’s choice to adhere or not to the treatment regimen 
depends on one’s beliefs about the disease and their perception of the importance of taking 
medication. Patient behavior for continued treatment, the persistence to treatment, once initi-
ated, is dependent on personal assessments of the obtained results.
5.2.2. Strategies for improving therapeutic adherence
Detection of nonadherence share among CV patients and medication noncompliant individ-
ual profile is very important but not enough to overcome this problem, if not followed by 
management plans and existing/emerging technologies. As the phenomenon of nonadher-
ence to therapy has grown in recent years, a number of interventions have been proposed to 
improve medication compliance of patients, which are centered in three directions: the health 
system, the therapist, and the patient, the three main players on which the therapeutic adher-
ence behavior of an individual depends. The health system should be so organized as to put 
more emphasis on the quality of care in both primary and secondary prevention, to take initia-
tives with regard to organizing health education and therapeutic programs for patients, to use 
counseling strategies in primary care as the patient’s motivational interventions for adoption 
of healthier CV lifestyles and reduction of their CVD risk, to monitor more closely the non-
compliance to treatment, and to find solutions to correct the potential problems in a timely 
manner; all these actions will lead to improvements in outcomes and cost savings. A number 
of interventions (improvement of physician-patient communication, counting pills, the use 
of reminder packaging or electronic event monitoring systems, etc.,) have been approached 
targeting individuals with medication adherence problems. The benefits were modest as 
specified by the trial results but had significant effects on medication-taking behavior [148, 
149]. The use of packaging interventions (like using pill boxes and blister packs, especially 
recommended for aging adults with multiple chronic diseases) effectively increase medication 
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adherence, aspect highlighted by a series of studies in this direction [150]. A review of different 
patient-centered interventions to increase adherence to treatment, which analyzed a total of 
141 studies, revealed that a major problem is the lack of patient knowledge about the disease 
and its proper medication, misunderstanding of their active and direct role responsible for the 
results of therapy, its relationship to their health and implicitly to HRQOL and their physi-
cal activity [151]. Since the HRQOL is a multidimensional evaluative concept that is based 
on the patients’ illness perception, the specialists’ attention should be centered less on the 
intrinsic disease outcomes (e.g., CV morbidity or mortality) and more on the changing percep-
tion outcomes in patients with CAD. In order to improve patient-centered care, counseling 
programs and therapeutic education of patients are, thus, necessary to be introduced. The lack 
or low levels of knowledge (both patients and their family members) is an important and foun-
dational element regarding their HF care regimen aspect supported by one’s education and 
counseling programs that have improved outcomes such as better adherence to a hygienic-
dietary regime, medication adherence, and a reduction in the rate of inpatient. All previous 
study results show that the presence of different CV risk factors in the general population and 
the emergence of the CVD, also, are related to a decreased QOL in these patients and support 
the idea that the events on healthcare education by health-related public programs should pro-
mote the importance of preventive measures associated with regular physical activity, with a 
special focus on women [114].
The conclusion derived from here regards the need to implement interventions on patient-
centered care and education. Increased awareness, knowledge, and education of CV patients 
especially on the benefits/risks of adherence/nonadherence to treatment is an essential com-
ponent in the increased ability of patients to manage their medication but not sufficient to 
ensure medication adherence and persistence. Alongside these educational programs, oth-
ers are required to improve the skills of self-control and auto-management of therapy and 
disease, aspects derived from the fact that in the long term, these patients need to rely on 
daily personal effort unattended closely by a therapist. When behavioral strategies are asso-
ciated with continuous therapeutic education programs, chances for adherence and persis-
tence to medication increase greatly for the CV patient and therapeutic results will not wait to 
happen. Furthermore, implementing individual educational sessions and not the group one 
may be better suited to the specific needs of each individual, contributing to a better therapy 
personalization.
6. Conclusion and suggestions for future developments
As a result of current developments in society, stress is a component increasingly present in 
everyday life of the individual and even a necessary one to a certain point. Due to the close 
interrelationship with the CV system (which responds first to its presence), excessive stress 
generates a range of behavioral disorders (e.g., unhealthy lifestyle) and pathophysiological 
changes which create conditions favoring development of CVD. Through the high mortality 
rate, they induce in the general population and from the perspective of evolutionary trend 
analysis studies, in 2020, CVD will become the pathology that generates the greatest economic 
burden in the world, as morbidity, disability, reduced QOL, and cause of death.
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Once triggered by induced pathophysiology changes, CVD also creates the prerequisites for 
the development of anxiety and mood disorders, and changes in patient behavior in this 
phase translate into a high rate of nonadherence to treatment. In these new conditions, it is 
required to implement ever more acutely in primary care practice of the CV patient strategies 
for the prevention of CVD and increasing/improving therapeutic adherence. An earlier iden-
tification of CV patient’s psychosocial profile in view of new discoveries and a patient-cen-
tered health education can help in reducing CV mortality and morbidity and thus improving 
their QOL.
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